<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061945</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02807</org_study_id>
    <secondary_id>NCI-2012-02807</secondary_id>
    <secondary_id>CDR302482</secondary_id>
    <secondary_id>CALGB 10102</secondary_id>
    <secondary_id>CALGB-10102</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <nct_id>NCT00061945</nct_id>
  </id_info>
  <brief_title>Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of alemtuzumab when given
      together with combination chemotherapy and to see how well it works in treating patients with
      untreated acute lymphoblastic leukemia. Monoclonal antibodies, such as alemtuzumab, can block
      cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
      Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs
      used in chemotherapy also work in different ways to kill cancer cells or stop them from
      growing. Giving alemtuzumab together with combination chemotherapy may be a better way to
      block cancer growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the feasibility and toxicity profiles of escalating doses of Campath-1H
      (alemtuzumab) given subcutaneously during post-remission intensification treatment of adults
      with acute lymphoblastic leukemia (ALL).

      II. To determine the disease-free survival (DFS) and overall survival (OS) when Campath-1H is
      used during post-remission intensification treatment of adults with ALL.

      III. To determine whether antibody treatment with Campath-1H can further reduce minimal
      residual disease states in adult ALL.

      IV. To obtain preliminary descriptive data on serum levels of Campath-1H during course IV,
      module D using limited pharmacokinetic sampling during the phase I and II components of the
      study.

      V. To obtain feasibility data on the addition of imatinib to Cancer and Leukemia Group B
      (CALGB) induction and postremission combination chemotherapy for patients with Philadelphia
      chromosome positive (Ph+) ALL.

      OUTLINE: This is a dose-escalation study of alemtuzumab.

      COURSE 1 (module A): Patients receive allopurinol orally (PO) 4 times daily (QID) on days
      1-14, cyclophosphamide* intravenously (IV) over 15-30 minutes on day 1, daunorubicin
      hydrochloride IV on days 1-3, vincristine sulfate IV on days 1, 8, 15, and 22, dexamethasone
      PO twice daily (BID) on days 1-7 and 15-21, asparaginase subcutaneously (SC) on days 5, 8,
      11, 15, 18, and 22, and filgrastim SC on days 4-11. Patients who are Ph+ also receive
      imatinib mesylate PO on days 15-28.

      *Note: Patients who are = 60 years old do not receive cyclophosphamide.

      COURSE 2 (module B): Patients receive methotrexate intrathecally (IT) on day 1, cytarabine IV
      over 3 hours on days 1-3, dexamethasone as eye drops QID on days 1-4,
      trimethoprim-sulfamethoxazole PO BID 3 times weekly on days 1-29, and cyclophosphamide,
      asparaginase and filgrastim as in course 1. Patients who are Ph+ also receive imatinib
      mesylate PO on days 1-28.

      COURSE 3 (module C): Patients receive vincristine sulfate IV on days 1, 15, and 29,
      methotrexate IV over 3 hours and IT on days 1, 15, and 19, methotrexate PO every 6 hours on
      days 1-2, 15-16, and 29-30, mercaptopurine PO on days 1-35, leucovorin calcium IV on days 2,
      16, and 30, leucovorin calcium PO every 6 hours on days 3-4, and
      trimethoprim-sulfamethoxazole PO BID 3 times weekly on days 1-43. Patients who are Ph+ also
      receive imatinib mesylate PO on days 1-42.

      COURSE 4 (module D): Patients receive alemtuzumab SC 3 times weekly for 4 weeks and begin
      acyclovir PO QID for 6 months (continuing through course 8).

        -  Phase I Cohort 1: 10 mg

        -  Phase I Cohort 2: 20 mg

        -  Phase I Cohort 3/Phase II MTD: 30 mg

      COURSE 5 (module A): Patients repeat course 1, minus allopurinol.

      COURSE 6 (module B): Patients repeat course 2.

      COURSE 7 (module C): Patients repeat course 3.

      COURSE 8: Patients receive mercaptopurine PO, vincristine sulfate IV on day 1, dexamethasone
      PO on days 1-5, methotrexate PO on days 1, 8, 15, and 22, and trimethoprim-sulfamethoxazole
      PO BID 3 days weekly. Patients who are Ph+ also receive imatinib mesylate PO on days 1-28.
      Courses repeat every 28 days for up to 24 months in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 6 months for 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The maximum tolerated dose is defined as the highest alemtuzumab dose at which less than 40% of patients develop the dose limiting toxicity (DLT), where DLT is defined as the inability to proceed (due to medical complications) with the protocol treatment within six weeks of receiving the last dose of alemtuzumab. Groups of six patients will be enrolled into each cohort at the time of re-registration prior to starting Course IV. After a cohort has accrued 6 patients and at least 3 have completed the 2-6 week post alemtuzumab observation period without DLT, the incoming patients will be assigned to the next cohort in the table while the DLT and other toxicities continue to be assessed for the newly closed cohort. If less than 3 out of 6 enrolled patients in a cohort have completed the 2-6 week post alemtuzumab observation period without DLT, additional patients may continue to enroll in that same cohort, i.e., accrual will not be suspended while waiting for patient follow-up data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)</measure>
    <time_frame>8 months</time_frame>
    <description>The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modulation of Minimal Residual Disease During Treatment With Alemtuzumab (Phase II)</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (Phase II)</measure>
    <time_frame>3 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method with confidence intervals presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Phase II)</measure>
    <time_frame>3 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method with confidence intervals presented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>B-cell Adult Acute Lymphoblastic Leukemia</condition>
  <condition>B-cell Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>L1 Adult Acute Lymphoblastic Leukemia</condition>
  <condition>L1 Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>L2 Adult Acute Lymphoblastic Leukemia</condition>
  <condition>L2 Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia</condition>
  <condition>Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia</condition>
  <condition>Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia</condition>
  <condition>T-cell Adult Acute Lymphoblastic Leukemia</condition>
  <condition>T-cell Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given PO and as eye drops</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IT, IV, and PO</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim-sulfamethoxazole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyclovir</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (alemtuzumab and combination chemotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unequivocal histologic diagnosis of precursor B or precursor T lymphoblastic leukemia
             (World Health Organization [WHO] classification), L1 or L2 ALL or acute
             undifferentiated leukemia (AUL) (French-American-British Cooperative group [FAB]
             Classification); Burkitt-type ALL (FAB L3, surface immunoglobulin [SIg]+) are excluded

          -  No prior treatment for leukemia with three permissible exceptions:

               -  Emergency leukapheresis II. Emergency treatment for hyperleukocytosis with
                  hydroxyurea III. Cranial radiation therapy (RT) for central nervous system (CNS)
                  leukostasis (one dose only)

          -  All patients must have a pre-treatment bone marrow or peripheral blood sample
             submitted for central immunophenotyping; only those patients who express CD52 &gt;= 10%
             in the leukemia blast cell channel will be eligible to receive Campath-1H during
             module D, course IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Stock</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <results_first_submitted>December 5, 2013</results_first_submitted>
  <results_first_submitted_qc>March 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2014</results_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From June 2003 to May 2007, a total of 302 participants were recruited.</recruitment_details>
      <pre_assignment_details>Two (2) participants cancelled prior to receiving any treatment and were removed from all analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I - Alemtuzumab and Combination Chemotherapy</title>
          <description>COURSE 1-allopurinol (ALL) orally (PO) 4x daily (QID) d1-14, cyclophosphamide (CTX) intravenously (IV) d1, daunorubicin IV d1-3, vincristine (VCR) IV d1,8,15 &amp; 22, dexamethasone (DEX) PO 2x daily (BID) d1-7 &amp; 15-21, asparaginase (APG) subcutaneously (SC) d5,8,11,15,18 &amp; 22, and filgrastim (FIL) SC d4-11. Ph+ pts imatinib (IMT) PO d15-28 COURSE 2-methotrexate (MTX) intrathecally (IT) d1, cytarabine IV d1-3, DEX eye drops QID d1-4, cotrimoxazole (CRT) PO BID 3x wkly d1-29 and CTX, APG &amp; FIL as course 1. Ph+ pts IMT PO d1-28 COURSE 3-VCR IV d1,15 &amp; 29, MTX IV &amp; IT d1,15 &amp; 19, MTX PO q6 hr d1-2,15-16 &amp; 29-30, mercaptopurine (6-MP) PO d1-35, leucovorin (LCV) IV d 2,16 &amp; 30, LCV PO q6 hr d3-4 &amp; CRT PO BID 3x wkly d1-43. Ph+ pts IMT PO d1-42 COURSE 4-alemtuzumab 10,20 or 30 mg SC 3x wkly q4 wk, acyclovir PO QID q6 mo COURSE 5-course 1 COURSE 6-course 2 COURSE 7-course 3 COURSE 8-6-MP PO, VCR IV d1, DEX PO d1-5, MTX PO d1,8,15 &amp; 22 and CRT PO BID 3d wkly. Ph+ pts IMT PO d1-28 q24 mo</description>
        </group>
        <group group_id="P2">
          <title>Phase II - Alemtuzumab and Combination Chemotherapy</title>
          <description>COURSE 1-allopurinol (ALL) orally (PO) 4x daily (QID) d1-14, cyclophosphamide (CTX) intravenously (IV) d1, daunorubicin IV d1-3, vincristine (VCR) IV d 1,8,15 &amp; 22, dexamethasone (DEX) PO 2x daily (BID) d 1-7 &amp; 15-21, asparaginase (APG) subcutaneously (SC) d 5,8,11,15,18 &amp; 22, and filgrastim (FIL) SC d 4-11. Ph+ pts imatinib (IMT) PO d 15-28 COURSE 2-methotrexate (MTX) intrathecally (IT) d1, cytarabine IV d1-3, DEX eye drops QID d 1-4, cotrimoxazole (CRT) PO BID 3x wkly d1-29 and CTX, APG &amp; FIL as course 1. Ph+ pts IMT PO d1-28 COURSE 3-VCR IV d 1,15 &amp; 29, MTX IV &amp; IT d 1,15 &amp; 19, MTX PO q6 hr d 1-2,15-16 &amp; 29-30, mercaptopurine (6-MP) PO d1-35, leucovorin (LCV) IV d 2,16 &amp; 30, LCV PO q6 hr d 3-4 &amp; CRT PO BID 3x wkly d1-43. Ph+ pts IMT PO d1-42 COURSE 4-alemtuzumab 30 mg SC 3x wkly q4 wk, acyclovir PO QID q6 mo COURSE 5-course 1 COURSE 6-course 2 COURSE 7-course 3 COURSE 8-6-MP PO, VCR IV d1, DEX PO d1-5, MTX PO d 1,8,15 &amp; 22 and CRT PO BID 3x wkly. Ph+ pts IMT PO d1-28 q24 mo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Registration Through Course 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Alemtuzumab Eligible</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early discontinuation during course I-IV</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Course IV: Alemtuzumab</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Declined Alemtuzumab</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early exits</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I - Alemtuzumab and Combination Chemotherapy</title>
          <description>See detailed description or participant flow.</description>
        </group>
        <group group_id="B2">
          <title>Phase II - Alemtuzumab and Combination Chemotherapy</title>
          <description>See detailed description or participant flow.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="181"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" lower_limit="30.5" upper_limit="59.8"/>
                    <measurement group_id="B2" value="46.5" lower_limit="29" upper_limit="58.4"/>
                    <measurement group_id="B3" value="46.8" lower_limit="29" upper_limit="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)</title>
        <description>The maximum tolerated dose is defined as the highest alemtuzumab dose at which less than 40% of patients develop the dose limiting toxicity (DLT), where DLT is defined as the inability to proceed (due to medical complications) with the protocol treatment within six weeks of receiving the last dose of alemtuzumab. Groups of six patients will be enrolled into each cohort at the time of re-registration prior to starting Course IV. After a cohort has accrued 6 patients and at least 3 have completed the 2-6 week post alemtuzumab observation period without DLT, the incoming patients will be assigned to the next cohort in the table while the DLT and other toxicities continue to be assessed for the newly closed cohort. If less than 3 out of 6 enrolled patients in a cohort have completed the 2-6 week post alemtuzumab observation period without DLT, additional patients may continue to enroll in that same cohort, i.e., accrual will not be suspended while waiting for patient follow-up data.</description>
        <time_frame>6 weeks</time_frame>
        <population>Only participants who started Alemtuzumab were analyzed per study design. Specifically, one patient declined Alemtuzumab and was excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I - Alemtuzumab and Combination Chemotherapy</title>
            <description>See detailed description or participant flow.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)</title>
          <description>The maximum tolerated dose is defined as the highest alemtuzumab dose at which less than 40% of patients develop the dose limiting toxicity (DLT), where DLT is defined as the inability to proceed (due to medical complications) with the protocol treatment within six weeks of receiving the last dose of alemtuzumab. Groups of six patients will be enrolled into each cohort at the time of re-registration prior to starting Course IV. After a cohort has accrued 6 patients and at least 3 have completed the 2-6 week post alemtuzumab observation period without DLT, the incoming patients will be assigned to the next cohort in the table while the DLT and other toxicities continue to be assessed for the newly closed cohort. If less than 3 out of 6 enrolled patients in a cohort have completed the 2-6 week post alemtuzumab observation period without DLT, additional patients may continue to enroll in that same cohort, i.e., accrual will not be suspended while waiting for patient follow-up data.</description>
          <population>Only participants who started Alemtuzumab were analyzed per study design. Specifically, one patient declined Alemtuzumab and was excluded from this analysis.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)</title>
        <description>The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV.</description>
        <time_frame>8 months</time_frame>
        <population>Only participants who started Alemtuzumab were analyzed per study design. Specifically, one patient declined Alemtuzumab and was excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II - Alemtuzumab and Combination Chemotherapy</title>
            <description>See detailed description or participant flow.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)</title>
          <description>The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV.</description>
          <population>Only participants who started Alemtuzumab were analyzed per study design. Specifically, one patient declined Alemtuzumab and was excluded from this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modulation of Minimal Residual Disease During Treatment With Alemtuzumab (Phase II)</title>
        <time_frame>Up to 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (Phase II)</title>
        <description>Will be estimated using the Kaplan-Meier method with confidence intervals presented.</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Phase II)</title>
        <description>Will be estimated using the Kaplan-Meier method with confidence intervals presented.</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Achieving Complete Remission</title>
        <description>A complete remission (CR) requires the following: an absolute neutrophil count (segs and bands) &gt; 1500/μl, no circulating blasts, platelets &gt; 100,000/μl; bone marrow cellularity &gt; 20% with trilineage hematopoiesis, and &lt; 5% marrow blast cells, none of which appear neoplastic. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement).</description>
        <time_frame>Duration of study (up to 10 years)</time_frame>
        <population>Three participants were deemed ineligible and excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I - Alemtuzumab and Combination Chemotherapy</title>
            <description>See detailed description</description>
          </group>
          <group group_id="O2">
            <title>Phase II - Alemtuzumab and Combination Chemotherapy</title>
            <description>See detailed description</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Complete Remission</title>
          <description>A complete remission (CR) requires the following: an absolute neutrophil count (segs and bands) &gt; 1500/μl, no circulating blasts, platelets &gt; 100,000/μl; bone marrow cellularity &gt; 20% with trilineage hematopoiesis, and &lt; 5% marrow blast cells, none of which appear neoplastic. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement).</description>
          <population>Three participants were deemed ineligible and excluded from this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phase I - Alemtuzumab and Combination Chemotherapy</title>
          <description>See detailed description or participant flow.</description>
        </group>
        <group group_id="E2">
          <title>Phase II - Alemtuzumab and Combination Chemotherapy</title>
          <description>See detailed description or participant flow.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="119"/>
                <counts group_id="E2" events="52" subjects_affected="44" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="86" subjects_affected="59" subjects_at_risk="119"/>
                <counts group_id="E2" events="146" subjects_affected="92" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ventricular bigeminy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Proptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="119"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="119"/>
                <counts group_id="E2" events="59" subjects_affected="48" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Endoscopy large bowel abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ileal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intestinal necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="35" subjects_affected="28" subjects_at_risk="119"/>
                <counts group_id="E2" events="78" subjects_affected="55" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oesophagoscopy abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rectal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Retroperitoneal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="119"/>
                <counts group_id="E2" events="53" subjects_affected="40" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E2" events="35" subjects_affected="26" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="42" subjects_affected="33" subjects_at_risk="119"/>
                <counts group_id="E2" events="82" subjects_affected="54" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Encephalomyelitis infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Infectious meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Joint infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="119"/>
                <counts group_id="E2" events="68" subjects_affected="52" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Small intestine infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Spinal cord infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Upper aerodigestive tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urethral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Viral hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vulval infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Esophageal anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Prolonged intubation after pulmonary resection (&gt;24 hrs after surgery)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" events="29" subjects_affected="24" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="39" subjects_affected="31" subjects_at_risk="119"/>
                <counts group_id="E2" events="83" subjects_affected="61" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="119"/>
                <counts group_id="E2" events="48" subjects_affected="44" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="119"/>
                <counts group_id="E2" events="82" subjects_affected="61" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="54" subjects_affected="48" subjects_at_risk="119"/>
                <counts group_id="E2" events="79" subjects_affected="59" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="119"/>
                <counts group_id="E2" events="50" subjects_affected="37" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QTc interval prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="119"/>
                <counts group_id="E2" events="42" subjects_affected="40" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" events="37" subjects_affected="22" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="81" subjects_affected="59" subjects_at_risk="119"/>
                <counts group_id="E2" events="137" subjects_affected="90" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="80" subjects_affected="59" subjects_at_risk="119"/>
                <counts group_id="E2" events="141" subjects_affected="89" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="119"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="75" subjects_affected="56" subjects_at_risk="119"/>
                <counts group_id="E2" events="122" subjects_affected="79" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="36" subjects_at_risk="119"/>
                <counts group_id="E2" events="63" subjects_affected="40" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="45" subjects_affected="37" subjects_at_risk="119"/>
                <counts group_id="E2" events="75" subjects_affected="52" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum calcium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum magnesium increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="119"/>
                <counts group_id="E2" events="64" subjects_affected="43" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="119"/>
                <counts group_id="E2" events="44" subjects_affected="35" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic nerve disorder NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypoglossal nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Mini mental status examination abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E2" events="36" subjects_affected="26" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Trigeminal nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Euphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ureteric hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E2" events="40" subjects_affected="29" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngeal examination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Respiratory tract hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="119"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bone marrow hypocellular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="55" subjects_at_risk="119"/>
                <counts group_id="E2" events="141" subjects_affected="93" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="352" subjects_affected="93" subjects_at_risk="119"/>
                <counts group_id="E2" events="650" subjects_affected="150" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Spleen disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Flashing vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Optic nerve edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="119"/>
                <counts group_id="E2" events="57" subjects_affected="45" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anal exam abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="36" subjects_affected="24" subjects_at_risk="119"/>
                <counts group_id="E2" events="87" subjects_affected="64" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="63" subjects_affected="47" subjects_at_risk="119"/>
                <counts group_id="E2" events="124" subjects_affected="80" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="37" subjects_affected="29" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="119"/>
                <counts group_id="E2" events="60" subjects_affected="48" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Esophageal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastric mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastroscopy abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="119"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="112" subjects_affected="59" subjects_at_risk="119"/>
                <counts group_id="E2" events="287" subjects_affected="121" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oesophagoscopy abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peritoneal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Salivary gland disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="54" subjects_affected="32" subjects_at_risk="119"/>
                <counts group_id="E2" events="142" subjects_affected="78" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E2" events="65" subjects_affected="46" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E2" events="78" subjects_affected="49" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="154" subjects_affected="64" subjects_at_risk="119"/>
                <counts group_id="E2" events="272" subjects_affected="116" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="119"/>
                <counts group_id="E2" events="76" subjects_affected="51" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Visceral edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Immune system disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="119"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Esophageal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ileal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Infection with grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Paranasal sinus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Penile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Phlebitis infective</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Salivary gland infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="39" subjects_affected="28" subjects_at_risk="119"/>
                <counts group_id="E2" events="64" subjects_affected="54" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="27" subjects_affected="16" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Small intestine infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urethral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Viral hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intraoperative hepatobiliary injury - Gallbladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intraoperative venous injury - Vein-superior vena cava</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Postoperative hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Prolapse of intestinal stoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ADH abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="38" subjects_affected="24" subjects_at_risk="119"/>
                <counts group_id="E2" events="64" subjects_affected="39" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="180" subjects_affected="66" subjects_at_risk="119"/>
                <counts group_id="E2" events="328" subjects_affected="122" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="68" subjects_affected="41" subjects_at_risk="119"/>
                <counts group_id="E2" events="163" subjects_affected="93" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="137" subjects_affected="59" subjects_at_risk="119"/>
                <counts group_id="E2" events="266" subjects_affected="108" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="131" subjects_affected="67" subjects_at_risk="119"/>
                <counts group_id="E2" events="174" subjects_affected="101" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood gonadotrophin abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="18" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="119"/>
                <counts group_id="E2" events="70" subjects_affected="40" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="66" subjects_affected="57" subjects_at_risk="119"/>
                <counts group_id="E2" events="118" subjects_affected="93" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="48" subjects_affected="25" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="36" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="45" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E2" events="123" subjects_affected="43" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="36" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E2" events="65" subjects_affected="30" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="312" subjects_affected="95" subjects_at_risk="119"/>
                <counts group_id="E2" events="575" subjects_affected="147" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="306" subjects_affected="93" subjects_at_risk="119"/>
                <counts group_id="E2" events="594" subjects_affected="149" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vital capacity decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="119"/>
                <counts group_id="E2" events="80" subjects_affected="54" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="281" subjects_affected="91" subjects_at_risk="119"/>
                <counts group_id="E2" events="426" subjects_affected="137" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" events="25" subjects_affected="15" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="99" subjects_affected="54" subjects_at_risk="119"/>
                <counts group_id="E2" events="170" subjects_affected="79" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="106" subjects_affected="62" subjects_at_risk="119"/>
                <counts group_id="E2" events="204" subjects_affected="97" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum calcium increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="34" subjects_affected="20" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E2" events="74" subjects_affected="43" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum magnesium increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E2" events="47" subjects_affected="39" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="78" subjects_affected="40" subjects_at_risk="119"/>
                <counts group_id="E2" events="184" subjects_affected="89" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="68" subjects_affected="39" subjects_at_risk="119"/>
                <counts group_id="E2" events="161" subjects_affected="84" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Serum triglycerides increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" events="79" subjects_affected="55" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Joint disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased lumbar spine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="32" subjects_affected="15" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E2" events="36" subjects_affected="26" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="38" subjects_affected="26" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic nerve disorder NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E2" events="51" subjects_affected="38" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="66" subjects_affected="39" subjects_at_risk="119"/>
                <counts group_id="E2" events="181" subjects_affected="88" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Mini mental status examination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E2" events="22" subjects_affected="14" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="129" subjects_affected="52" subjects_at_risk="119"/>
                <counts group_id="E2" events="194" subjects_affected="83" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E2" events="44" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="119"/>
                <counts group_id="E2" events="46" subjects_affected="26" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E2" events="48" subjects_affected="31" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemoglobin urine positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Feminization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ovulation pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vaginal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="24" subjects_affected="14" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="119"/>
                <counts group_id="E2" events="102" subjects_affected="55" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="21" subjects_at_risk="119"/>
                <counts group_id="E2" events="74" subjects_affected="48" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Laryngoscopy abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngeal examination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngeal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Respiratory tract hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tracheoscopy abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="24" subjects_at_risk="119"/>
                <counts group_id="E2" events="57" subjects_affected="33" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="119"/>
                <counts group_id="E2" events="97" subjects_affected="65" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="119"/>
                <counts group_id="E2" events="37" subjects_affected="35" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wendy Stock, M.D.</name_or_title>
      <organization>University of Chicago Medical Center</organization>
      <email>wstock@medicin.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

